Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FMISO PET/CT for Hypoxia in Soft Tissue Sarcomas
NCT03730077Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluoromisonidazole in soft tissue sarcoma (STS) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Hypoxia in FMISO PET/CT at 2 years. Started Feb 2019; status: terminated.
02
Drugs
fluoromisonidazole
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03730077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730077.